Pennsylvania is currently home to 3306 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
NCT06688396
Recruiting
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Dilated Cardiomyopathy, Heart Failure, Heart Disease
Register for Updates
Hypofractionated WPPT With HDR Boost
NCT06591819
Recruiting
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
NCT06557785
Recruiting
This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses are: 1. the CH505M5 N197D mRNA-gp160 will expand CH235-like B cell precursors, 2. the CH505 TF mRNA-gp160 will boost CH235-like bnAb B cell precursors to acquire more functional m... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/28/2025
Locations: Penn Prevention (Site ID: 30310), Philadelphia, Pennsylvania
Conditions: HIV Infections
Register for Updates
Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD with Fentanyl Use
NCT06379984
Recruiting
The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug test. Participants will be admitted to a monitored research unit for the trial. They will be randomized to start buprenorphine with either standard initiation or with a new approach called rapid outpat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pennsylvania Center for Studies of Addiction, Philadelphia, Pennsylvania
Conditions: Opioid Use Disorder
Register for Updates
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
NCT06271291
Recruiting
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pancreatic Carcinoma
Register for Updates
SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
NCT06208748
Recruiting
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Gastrointestinal Stromal Tumors, GIST
Register for Updates
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
NCT06056102
Recruiting
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of 99.5% or higher means that your immune system would reject 99.5% of kidneys available for transplant. The study will test whether new products called Chimeric Antigen Receptor T Cells (CAR T Cells), when given with chemotherapy, is safe and will reduce cPRA. The main study will last up to 2 years: Participants will have up to 30 clinic o... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/28/2025
Locations: University of Pennsylvania Medical Center (Site #: 71111), Philadelphia, Pennsylvania
Conditions: Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
Register for Updates
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
NCT05831176
Recruiting
The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the eff... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis, Eosinophilic Gastrointestinal Disease
Register for Updates
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT05710328
Recruiting
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Bryn Mawr Hospital, Bryn Mawr, Pennsylvania
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT04631744
Recruiting
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/28/2025
Locations: University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
NIH R01 Friend to Friend With Coaching
NCT04164472
Recruiting
This study examines the effectiveness of the Friend to Friend (F2F) program when conducted by teachers and counselors with active coaching from the research team. The project involves 14 small group sessions for relationally aggressive girls and 8 classroom sessions. Students, teachers, counselors and parents at intervention and control schools fill out pre- and post- program questionnaires.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Aggression
Register for Updates
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates